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Patients with cancer have prothrombotic and hypercoagulable state, which leads to
higher risk for venous thromboembolism and other clinical manifestations of throm-
boses. Pathophysiology of thrombosis in cancer patients is influenced by many
factors, different from patients without malignancy. Tumor cells express tissue factor
and other procoagulant factors and during tumors invasive growth, dissemination and
metastasis process tumor cells interact with endothelial cells, leukocytes, monocytes
and platelets. Increased platelet activation and aggregability as well as changes in
coagulation and fibrinolysis are present in cancer and especially in metastatic disease.
Higher risk for venous thromboembolism is well known in patients with cancer during
hospitalization, in patients with malignancy before, during and after operation, during
ambulatory active chemotherapy, as well as in patients with different kinds of
adjunctive therapy. Associated complications such as pulmonary embolism and
others are associated with the increase of early mortality in these patients. Prevention
of venous thromboembolism in this population is recommended in nearly all patients,
especially in patients with prior venous thromboembolism or pulmonary embolism.
Drugs of choice are low-molecular weight heparins, unfractionated heparin, vitamin K
antagonists and fondaparinux. With the evolution of new anticoagulants which are
coming to clinical praxis such as dabigatran, we can expect their further use for
prevention in cancer patients in the future.
& 2013 The Czech Society of Cardiology. Published by Elsevier Urban & Partner Sp.z o.o.
All rights reserved.
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The association between cancer and thromboembolism was
described first in 1865 by Trousseau who noticed association
between malignant disease and venous thrombosis [1]. Much
later, autopsy rates showed that occurrence of venous throm-
boembolism (VTE) in cancer patients could be up to 50% [2–4],
clinically detectable VTE is found in 4–20% of patients and now
it is well known that VTE is one of the leading causes of deaths
in patients with cancer [5]. Some types of cancer are more
likely to be prothrombotic, and several studies confirmed
changes in clotting factors in following tumors: solid cancers,
ductal adenocarcinoma of pancreas, colorectal carcinoma,
melanoma, breast cancer, gastrointestinal cancer, gynecologi-
cal cancers, cervical and endometrial cancer, myeloma and
other hematological cancers. Prothrombotic state in these
patients is also influenced by many other factors: disease
stage, hospitalization, immobilization as well as surgery and
chemotherapy. The risk of development of VTE in hospitalized
patients with cancer is 4.1 times higher than in patients
without cancer; the risk is higher when chemotherapy is used
[6,7]. The incidence of VTE with the use of new antiangiogenic
drugs and cancer regimens including thalidomide, lenalido-
mide or bevacizumab is also higher than before [8–11]. Deep
vein thrombosis is the most common clinical presentation of
prothrombotic state in cancer patients, but arm vein throm-
bosis, pulmonary embolism, migratory superficial thromboph-
lebitis, thrombotic microangiopathy and cerebral sinus
thrombosis can also occur in cancer sometimes before the
detection of cancer. Thromboses may also occur in arterial
system and it is estimated that from all thromboses about 25%
are arterial ones.2. Risk factors for cancer associated VTE
There is evidence that the risk of deep vein thrombosis (DVT)
and VTE depends on tumor type, stage and extent of cancer
and treatment used. The role of risk factors such as treatment
during hospitalization, immobilization, obesity, varicose veins
has been evaluated by Kro¨ger et al. [12]. Several risk factors
have been shown to increase risk of VTE in their study, starting
from history of prior DVT, or family history of DVT, chemother-
apy and fever. The only laboratory parameter which reached
statistical significance was C-reactive protein. When the che-
motherapy used was looked at, the following drugs influencedthe incidence of VTE significantly: anthracyclines, platinum
based drugs and nitrogen mustard analogs. Other risk factors
such as age, gender, obesity, chronic venous insufficiency, time
from first diagnosis of cancer or diarrhea had only a minor role
for VTE in patients with malignancy. They concluded that the
risk of DVT in cancer patients without additional risk factors is
low, but the risk is increasing with the increasing number of
risk factors present in individual patient. The risk assessment
is therefore very important to identify high risk patients with
further application of prophylactic treatment.3. Specifics of thrombosis pathophysiology
in cancer patients
There are several different aspects of the cause of thrombosis
in cancer; the presence of a tumor itself is the factor for
development of prothrombotic state. Increased platelet acti-
vation and aggregability as well as changes in coagulation
and fibrinolysis are present in cancer and especially in
metastatic disease [13]. In cancer patients, hypercoagulable
state with abnormalities of three basic components of Virch-
ow’s triad is common. Abnormal blood flow, abnormal blood
constituents and abnormalities of the vessel wall represent
three main parts of this triad, and mechanisms leading to
prothrombogenicity are multiple and synergistic.4. Abnormal blood flow
This component of Virchow’s triad is probably less important
in cancer patients than in patients with cardiovascular
diseases. However, altered blood viscosity and yield stress
was found in patients with abdominal malignancy and a
relationship of this to deep vein thrombosis was shown
already many years ago [14]. Important role plays increased
stasis during immobility of patients. Other possibilities in
this component of triad represent abnormal blood vessel
formation due to cancer based neoangiogenesis [15].5. Abnormal blood constituents in cancer
patients
Generally, several changes are pronounced in patients with
malignancy: increased platelet activation and aggregation,
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and fibrinolytic factors.
5.1. Platelets
It was shown that in myeloma and in cervical and endome-
trial cancer there is reduced sensitivity to prostacyclin,
resulting in increased platelet aggregability [16]. Also in lung,
breast, ovarian and prostate cancers higher levels of platelet
products such as beta-thromboglobulin, platelet factor 4,
thrombospondin and soluble P-selectin are found [17]. There
are several possible explanations for the excess platelet
activity: when studied in vitro, cancer cells activate platelets
by direct contact, with the release of platelet activators such
as thromboxane A2 and ADP; also an increase of von Will-
ebrand factor (vWF), fibrinogen and PAI-1 has been demon-
strated in cancer patients [18].
5.2. Clotting—fibrinolytic system
Other mechanisms of prothrombotic state are related to
coagulation—some degree of altered coagulation can be
found in most of the cancer patients. Soluble plasma mole-
cules are involved in both procoagulant and fibrinolytic
systems and their balance is shifted to prothrombotic state
in cancer patients. Monocytes have important role in these
pathological changes. Their ability to express tissue factor as
well as delivery of cytokines and procoagulant activities of
monocyte microparticles is important, which have potential
role to promote thrombosis in patients with malignancy.6. Role of the tissue factor and the cancer
procoagulant
Tissue factor is produced by monocytes and endothelial cells;
in cancer its production is upregulated due to high circulating
concentrations of vascular endothelial growth factor (VEGF).
Rickles et al. [19,20] showed that tissue factor can be
expressed also by tumor cells, including sarcoma, melanoma,
lymphoma, neuroblastoma and acute promyelocytic leuke-
mia cells. It has been suggested that tissue factor is a marker
for switching to an angiogenic and prothrombotic phenotype
for instance as in breast cancer. Other less known direct
activator of coagulation is a cysteine proteinase growth
factor—cancer procoagulant, which activates directly factor X.
Increased concentrations of cancer procoagulant have been
found in patients with malignant melanoma, acute promye-
lolytic leukemia, and cancer of colon, breast, lung and kidney
[21,22].
6.1. Coagulation cascade
Changes of proteins within coagulation cascade were found in
many studies in cancer patients. For example, increased
plasma concentrations of thrombin–antithrombin III com-
plexes, as well as increased fibrinogen and vWF have been
observed in patients with breast cancer. Also reduced concen-
trations of tissue plasminogen activator with concomitant
increased plasminogen activator inhibitor-1 and otherinhibitory factors in fibrinolytic pathway were found in
patients with gastrointestinal cancer which resulted in pro-
thrombotic and hypercoagulable state. In lung cancer
thrombosis-inducing activities increase with the stage of the
disease of all cell types and are associated with shorter survival
time in inoperable non-small-cell lung cancer [23]. Elevated
levels of D-dimer were found in numerous studies in patients
with VTE and malignancy, and also in patients with cancer
who do not have VTE. It has been suggested that high D-dimer
levels in malignancy reflect the biology of the tumor itself;
higher levels were observed in breast, bowel and prostate
cancers [24].
6.2. Abnormalities of vessel wall
Endothelial function may be assessed by plasma changes of
several molecules such as soluble E-selectin, thrombomodu-
lin and vWF. Endothelial cells are influenced by pro-
inflammatory cytokines like interleukin-1 and tumor necrosis
factor, resulting in suppression of endothelial fibrinolytic
activity and increase of production of vWF and thrombomo-
dulin, which leads to decrease of anticoagulant thrombomo-
dulin on endothelial surface. The role of vWF in promoting
thrombosis in cancer patients is well known—its increase
indicates endothelial damage; it can also increase fibrinogen
level and contribute to platelet to platelet and platelet to
subendothelium adhesion. Similarly, thrombomodulin is
increased in cancer and can promote coagulopathy in these
patients.
6.3. Recommendations for prevention of VTE in cancer
patients
American Society of Clinical Oncology summarized recom-
mendation for the use of anticoagulation in the prevention of
VTE in patients with malignancy in 2007 [25]. These recom-
mendations are based on several well known facts: tumor
cells express tissue factor and other procoagulant factors and
during tumor’s invasive growth, dissemination and metasta-
sis process tumor cells interact with endothelial cells, leuko-
cytes, monocytes and platelets. Also immobilization and
chemotherapy increase risk of changes in hemostasis with
subsequent thrombotic complications. Inhibiting of hemos-
tasis by different drugs may change biology of cancer and can
modify direct effect of thromboses on patient survival.
6.4. Anticoagulation therapy during hospitalization
The frequency of venous thrombosis in hospitalized patients
with cancer is reported with incidences ranging between 0.6%
and 18% (Lyman Table 2 [25]). Higher incidence of VTE is
common in patients with malignancy of the brain, gastro-
intestinal tract, ovary, kidney, pancreas, bladder, lung and
hematologic malignancies [26]. Also older patients and
patients on hormonal therapy are at higher risk for VTE, as
well as patients with central venous catheters. Therefore,
patients with cancer should be considered candidates for VTE
prophylaxis with anticoagulants during hospitalization in the
absence of bleeding or other contraindications to anticoagu-
lation. Multiple randomized clinical trials focused on
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which prophylaxis with either low-dose heparin or low-
molecular-weight-heparin (LMWH) for bedridden patients is
strongly recommended [27].7. Perioperative VTE prophylaxis
Risk of DVT during surgery in cancer patients is about double
when compared with patients without cancer [28]; therefore
all patients undergoing major surgical intervention for malig-
nant disease should receive drugs for thrombosis prophylaxis.
Up to 25% of symptomatic VTE occurs after discharge from the
hospital; the @RISTOS project showed that 40% of VTE events
occurred three weeks after surgery and VTE was responsible
for 46% of deaths in the first month after the surgery [29].
In patients undergoing surgery VTE prophylaxis can be mechan-
ical or pharmacological. Prevention of venous stasis is either
passive with graduated compression stockings, or active with
intermittent pneumatic calf compression or mechanical foot
pumps. The reduction of VTE with these methods reduced
frequency of DVT by 66%, but reduction of pulmonary embo-
lism was only 31% when pooled data from three studies were
analyzed [30]. For pharmacological VTE prophylaxis the use of
several drugs is common, including unfractionated heparin
(UFH), low molecular weight heparins (LMWHs), fondaparinux
and vitamin K antagonists. Low-dose UFH has been used for
perioperative prevention of DVT and PE in cancer patients for
years. The meta-analysis of 10 trials published in 1998 showed
that administration of low-dose UFH decreased rates of
incidence of DVT from 30.6% in control group to 13.6% in the
active treatment group (po0.001) [31]. Low molecular weight
heparins are currently used more often and their comparison
with UFH showed similar efficacy in DVT prevention [32]. Once
daily s.c. injection and lower risk of heparin induced throm-
bocytopenia are the main potential advantages of LMWH over
UFH. Bergqvist et al. demonstrated that in patients with cancer
undergoing laparotomy, an increasing dose of LMWH (2500 U
versus 5000 U) can improve prophylactic efficacy without
increasing the risk of bleeding [33]. Inhibitor of factor Xa,
fondaparinux, was found to be at least as effective as LMWH
dalteparin in randomized clinical trial with 2048 patients
undergoing abdominal surgery; 68% of them were patients
with cancer [29]. The duration of prophylaxis prevention is
also a factor of high importance—4 weeks prophylaxis with
enoxaparin was more effective than 1 week duration enox-
aparin in randomized trial focused on incidence of DVT after
abdominal or pelvic cancer surgery [34].
7.1. Anticoagulation therapy during systemic outpatients
chemotherapy
In ambulatory patients with cancer, routine prophylaxis of
DVT and PE during systemic chemotherapy is not recom-
mended. Available data from clinical trials are conflicting:
generally, the risk of VTE is relatively low, but non-
randomized clinical trials of thalidomide containing regi-
mens showed risk of VTE in 17% of patients and even in
26% when its combination with dexamethazone was used.
Prophylactic anticoagulation with combination of LMWH,warfarin 1.25 mg and antiaggregation with aspirin showed
efficacy in prevention of DVT in patients receiving thalido-
mide for multiple myeloma [35]. But generally, the use of
aspirin is not recommended due to higher risk of bleeding in
cancer patients [36]
7.2. Prevention of recurrent VTE for patients with
established VTE
When VTE is diagnosed in cancer patients, the indication for
anticoagulant therapy is essentially the same as for patientswho
do not have cancer. LMWHs are the preferred mode of treatment
for initial 5–10 days; for long-term anticoagulant therapy LMWHs
are also the treatment of first choice. When LMWHs are not
available, vitamin K antagonists with targeted INR 2–3 are
usually used. The CLOT study (Randomized Comparison of
Low-Molecular-Weight Heparin Versus Oral Anticoagulant Ther-
apy for the Prevention of Recurrent Venous Thromboembolism
in Patients with Cancer) randomly compared LMWH (dalteparin
200 IU/kg body weight s.c. once daily 5–7 days) followed by
coumarin derivative for the next 6 months versus dalteparin
alone – first month 200 IU/kg body weight followed by 150 IU/kg
body weight for next 5 months – in patients with cancer and VTE
[37]. The recurrent symptomatic VTE occurred in 9% of patients
in dalteparin-alone group versus 17% in the coumarin group
(p¼0.002). Major bleeding was present in 6% vs. 4%; any bleeding
in 14% vs. 19% in dalteparin coumarin group and this difference
was not statistically significant in both comparisons. Other
randomized trial compared enoxaparin 1.5 mg/kg once daily
s.c. with warfarin in 147 patients with cancer and VTE. The
incidence of recurrent VTE or major bleeding was higher in
warfarin group—21.1% vs. 10.5% (p¼0.09). Currently LMWHs are
approved in the USA for extended treatment of symptomatic
VTE in patients with malignancy [38].8. Conclusions
Patients with cancer have prothrombotic and hypercoagulable
state, which leads to higher risk for venous thromboembolism
and other clinical manifestations of thromboses. Associated
complications such as pulmonary embolism and others are
associated with the increase of early mortality in these
patients. Prevention of VTE in this population is recommended
especially in several groups of cancer patients who have
higher risk of VTE: those are patients with prior VTE or PE,
patients during hospitalization, patients with malignancy
before, during and after surgical therapy, patients on active
chemotherapy on an ambulatory basis as well as patients with
different kinds of adjunctive therapy. Drugs of choice are low-
molecular weight heparins, unfractionated heparin, vitamin K
antagonists and fondaparinux. With the evolution of new
drugs for VTE prevention we can expect their further use for
prevention in cancer patients in the future as well.
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